John F. Neylan
2017
In 2017, John F. Neylan earned a total compensation of $1.3M as Chief Medical Officer at Keryx Biopharmaceuticals, a 25% increase compared to previous year.
Compensation breakdown
| Non-Equity Incentive Plan | $161,257 |
|---|---|
| Option Awards | $386,042 |
| Salary | $428,047 |
| Stock Awards | $269,588 |
| Other | $6,192 |
| Total | $1,251,126 |
Neylan received $428K in salary, accounting for 34% of the total pay in 2017.
Neylan also received $161.3K in non-equity incentive plan, $386K in option awards, $269.6K in stock awards and $6.2K in other compensation.
Rankings
In 2017, John F. Neylan's compensation ranked 7,903rd out of 14,666 executives tracked by ExecPay. In other words, Neylan earned more than 46.1% of executives.
| Classification | Ranking | Percentile |
|---|---|---|
All | 7,903 out of 14,666 | 46th |
Division Manufacturing | 2,965 out of 5,772 | 49th |
Major group Chemicals And Allied Products | 968 out of 2,075 | 53rd |
Industry group Drugs | 754 out of 1,731 | 56th |
Industry Pharmaceutical Preparations | 591 out of 1,333 | 56th |
Source: SEC filing on May 31, 2018.
Neylan's colleagues
We found four more compensation records of executives who worked with John F. Neylan at Keryx Biopharmaceuticals in 2017.